A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain

Pulmonary Arterial Hypertension Clinical Trial

— ORCHESTRA  

Official title:

A Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the French, Italian and Spanish Versions of the PAH-SYMPACT™

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02081690
• Other study ID #: AC-055-310
• Status: Terminated
• Phase: Phase 3
• First received: March 5, 2014
• Last updated: February 22, 2018
• Start date: March 1, 2014
• Est. completion date: November 1, 2015

Study information

• Verified date: February 2018
• Source: Actelion
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective, multi-center, open-label, single-arm, Phase 3b psychometric validation study.

Primary objectives: To evaluate the psychometric characteristics of reliability and construct validity of the French, Italian and Spanish versions of the PAH-SYMPACT™.

To evaluate the ability of the French, Italian and Spanish versions of the PAH SYMPACT™ to detect change.

Secondary objective: To assess the safety of macitentan in patients with pulmonary arterial hypertension (PAH).

Exploratory objective: To explore the effects of macitentan on PAH symptoms and their impact (as measured by the PAH-SYMPACT™) in patients with PAH in France, Italy and Spain.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 160
• Est. completion date: November 1, 2015
• Est. primary completion date: October 1, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Signed informed consent prior to initiation of any study-mandated procedure.

2. Patients with symptomatic PAH in WHO Functional Class (FC) II or III.

3. Patients with PAH belonging to one of the following subgroups of the Dana Point Clinical Classification Group 1:

1. Idiopathic, or,

2. Heritable, or,

3. Drug or toxin induced, or,

4. Associated with one of the following:

i. Connective tissue disease, ii. Congenital heart disease with simple systemic-to-pulmonary shunt at least 1 year after surgical repair, iii. HIV infection.

4. Documented hemodynamic diagnosis of PAH by right heart catheterization - performed at any time prior to Screening showing:

1. Resting mean pulmonary arterial pressure (mPAP) = 25 mmHg and,

2. Resting pulmonary vascular resitance (PVR) > 240 dyn.s.cm-5 and,

3. Pulmonary capillary wede pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) = 15 mmHg.

5. 6-minute walk distance (6MWD) = 150 m at Screening.

6. Able to fluently speak and read the local language.

7. Men or women aged 18-80; women of childbearing potential (as defined below) must:

1. Have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline and agree to perform monthly serum pregnancy tests, and,

2. Agree to use two reliable methods of contraception in parallel, from Screening Visit 1 until 1 month after study drug discontinuation (see details below).

• A female is considered to have childbearing potential unless she meets at least one of the following criteria:

• Previous bilateral salpingo and/or oophorectomy, or hysterectomy.

• Premature ovarian failure confirmed by a specialist.

• Pre-pubescence, XY genotype, Turner syndrome, uterine agenesis.

• Postmenopausal, defined as 12 consecutive months with no menses without an alternative medical cause.

• Of the two contraceptive methods that must be used, one must be from Group 1, and one must be from Group 2, defined as follows:

• Group 1: Oral, implantable, transdermal or injectable hormonal contraceptives, intrauterine devices, female sterilization (tubal ligation or non surgical sterilization, e.g., permanent contraception with Essure procedure), or partner's sterilization (vasectomy). If a hormonal contraceptive is chosen from this group, it must be taken for at least 1 month prior to enrollment. Alternatively, if the Essure procedure is chosen as a contraceptive method, a hysterosalpingogram must have been performed to confirm correct location of the microinserts and tubal occlusion (as per manufacturer's recommendations).

• Group 2: Female or male condoms, diaphragm or cervical cap, any of them in combination with a spermicide.

• Sexual abstinence, rhythm methods, or contraception by the partner alone are not considered as acceptable methods of contraception for this study.

Exclusion Criteria:

1. Known moderate-to-severe obstructive lung disease (i.e., forced expiratory volume in one second [FEV1] < 80 % of predicted, with FEV1 / forced vital capacity [FVC] < 70%) or known significant chronic lung disease diagnosed by chest imaging (e.g., interstitial lung disease, emphysema).

2. Known moderate-to-severe restrictive lung disease (i.e., total lung capacity [TLC] < 60% of predicted value).

3. Hemoglobin < 100g/L at Screening.

4. Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 3 X upper limit of the normal range (ULN) at Screening.

5. Patients undergoing dialysis.

6. Systolic blood pressure (SBP) < 90 mmHg at Screening.

7. Body weight < 40 kg at Screening.

8. Known concomitant life-threatening diseases with a life expectancy of < 12 months.

9. Treatment with ERAs within 3 months prior to Visit 2, or scheduled to receive any of these compounds, other than macitentan, during the trial.

10. Treatment with intravenous or subcutaneous prostacyclin or prostacyclin analogs within 3 months prior to Visit 2, or scheduled to receive any of these compounds during the trial.

11. Treatment with soluble guanylate cyclase stimulator (riociguat) within 3 months prior to Visit 2, or scheduled to receive riociguat during the trial.

12. Patients who changed the dose of or discontinued phosphodiesterase type-5 inhibitor (PDE5i), inhaled prostacyclin analogues, or calcium channel blockers within 3 months prior to Visit 2.

13. Initiation of diuretics within 1 week prior to the Baseline period.

14. Patients on oral diuretics in whom the dose has not been stable for at least 1 week prior to the Baseline period.

15. Treatment with cytochrome P4500 (CYP) 3A inducers within 4 weeks prior to Visit 2.

16. Recently started (< 8 weeks prior to Visit 2) or planned cardio-pulmonary rehabilitation program based on exercise.

17. Females who are lactating or pregnant (positive Screening or Baseline pregnancy test) or plan to become pregnant during the study.

18. Known hypersensitivity to macitentan or its excipients or drugs of the same class.

19. Treatment with another investigational drug within 3 months prior to Visit 2.

20. Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease.

Related Conditions & MeSH terms

• Familial Primary Pulmonary Hypertension
• Hypertension
• Pulmonary Arterial Hypertension

Intervention

Drug:
• Macitentan
Macitentan tablet, dose of 10 mg, once daily

Locations

Country	Name	City	State
France	Hôpital de Haut Levêque	Bordeaux
France	Hôpital Côte de Nacre	Caen
France	Hôpital Albert Michallon	Grenoble
France	CHU de Bicêtre	Le Kremlin-Bicêtre
France	CHRU Lille - Hôpital Cardiologique	Lille
France	Hôpital Louis Pradel	Lyon
France	Hôpital Arnaud de Villeneuve	Montpellier
France	Hôpitaux de Brabois	Nancy
France	Hôpital Pontchaillou	Rennes
France	Hôpital Charles Nicolle	Rouen
France	Hôpital Nord	Saint-Etienne
France	Hôpital Civil	Strasbourg
France	Hôpital Larrey	Toulouse
Italy	Ospedale di Venere	Bari
Italy	Universita degli Studi di Bari	Bari
Italy	Ospedale Sant'Orsola	Bologna
Italy	A.O.U.C. Careggi	Firenze
Italy	Milan Sacco Hospital	Milan
Italy	AORN Azienda Ospedaliera dei Colli	Naples
Italy	Ambulatorio Scompenso Cardiaco e Trapiant	Pavia
Italy	Istituto di Fisiologia clinica - CNR	Pisa
Italy	Centro Per La Diagnosi E La Cura Dell'Ipertensione Polmonare	Roma
Italy	UOC Immunologia Clinica B-PGRM Centro di Riferimento per la Sclerosi Sistemica	Rome
Italy	Ospedale "S. Maria di Cà Foncello"	Treviso
Italy	Policlinico G.B. Rossi	Verona
Spain	Hospital General de Alicante	Alicante
Spain	Hospital Clinic	Barcelona
Spain	Hospital Val Hebron	Barcelona
Spain	Hospital de Cruces	Bilbao
Spain	Hospital Reina Sofia	Córdoba
Spain	Hospital Dr Negrin	Las Palmas de Gran Canaria
Spain	Hospital Universitario Insular Gran Canarias	Las Palmas de Gran Canaria	Islas Canarias
Spain	Hospital 12 Octubre	Madrid
Spain	Hospital La Paz	Madrid
Spain	Hospital Carlos Haya	Malaga
Spain	Hospital Son Espases	Palma de Mallorca
Spain	Hospital de Valdecilla	Santander
Spain	Hospital Virgen del Rocio	Sevilla
Spain	Hospita General U. Valencia	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Actelion

Countries where clinical trial is conducted

France,  Italy,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of the Reliability and the Construct Validity of the Cardiopulmonary Symptoms Domain of the PAH-SYMPACT	The Cardiopulmonary Symptoms domain consists of 6 items reported on a 5-point Likert scale (from 0 to 4). The value 0 means "no symptom" and value 4 corresponds to "very severe symptoms".The symptoms part of the PAH-SYMPACT was administered daily over a 7 day period. The recall period of symptom items is the last 24 hours. An average Cardiopulmonary Symptoms domain score is determined based on the daily scores of the 6 items. It was administered two times (daily during 7 days each time) prior to administration of Macitentan (Visit 2, Baseline) and daily during the 7-day period in the treatment period prior to Visit 3 (Week 8) and Visit 4 (Week 16).	From Screening Visit (Visit 1) to End of Treatment (EOT) Visit (Visit 4, Week 16)
Primary	Evaluation of the Reliability and the Construct Validity of the Cardiovascular Symptoms Domain of the PAH-SYMPACT	The Cardiovascular Symptoms domain consists of 5 items reported on a 5-point Likert scale (from 0 to 4). The value 0 corresponds to "no symptoms" and value 4 corresponds to "very severe symptoms". The symptoms part of the PAH-SYMPACT was administered daily over a 7 day period. The recall period of symptom items is the last 24 hours. An average Cardiovascular Symptoms domain score is determined based on the daily scores of the 5 items. It was administered two times (daily during 7 days each time) prior to administration of Macitentan (Visit 2, Baseline) and daily during the 7-day period in the treatment period prior to Visit 3 (Week 8) and Visit 4 (Week 16).	From Screening Visit (Visit 1) to End of Treatment (EOT) Visit (Visit 4, Week 16)
Primary	Evaluation of the Reliability and the Construct Validity of the Physical Impacts Domain of the PAH-SYMPACT	The Physical Impacts domain consists of 7 items reported on a 5-point Likert scale (from 0 to 4). The value 0 corresponds to "not at all"/"with no difficulty at all" and value 4 corresponds to "very much"/"extremely"/ "not able at all". The impacts part of the PAH-SYMACT was administered on Day 7 of the symptoms part administration. Items in the impact part have a 7 day recall period. An average Physical Impacts domain score is determined based on the 7 items in the domain. It was administered two times prior to administration of Macitentan (Visit 2, Baseline) and during the 7-day period in the treatment period prior to Visit 3 (Week 8) and Visit 4 (Week 16).	From Screening Visit (Visit 1) to End of Treatment (EOT) Visit (Visit 4, Week 16)
Primary	Evaluation of the Reliability and the Construct Validity of the Cognitive/Emotional Impacts Domain of the PAH-SYMPACT	The Cognitive/Emotional Impacts domain consists of 4 items reported on a 5-point Likert scale (from 0 to 4). The value 0 corresponds to "not at all"/"with no difficulty at all" and value 4 corresponds to "very much"/"extremely"/ "not able at all". The impacts part of the PAH-SYMACT was administered on Day 7 of the symptoms part administration. Items in the impact part have a 7 day recall period. An average Cognitive/Emotional Impacts domain score is determined based on the 4 items in the domain. It was administered two times prior to administration of Macitentan (Visit 2, Baseline) and during the 7-day period in the treatment period prior to Visit 3 (Week 8) and Visit 4 (Week 16)."	From Screening Visit (Visit 1) to End of Treatment (EOT) Visit (Visit 4, Week 16)